Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Aroa Biosurgery says Symphony DFU trial lifts 12-week complete closure rate to 55% vs 35% with standard care

Aroa Biosurgery says Symphony DFU trial lifts 12-week complete closure rate to 55% vs 35% with standard care

BitgetBitget2026/10/05 04:46

Aroa Biosurgery reported results from a randomized trial of Symphony for diabetic foot ulcers, published in the International Wound Journal. The study results have already been presented through publication, not flagged for a future conference release. Patients receiving Symphony with standard care saw better healing outcomes than standard care alone, with more wounds closing fully. Healing also occurred faster in the Symphony group, supporting a stronger clinical value proposition for reimbursement and adoption. The trial enrolled 143 patients across 10 U.S. sites, targeting harder-to-treat ulcers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aroa Biosurgery Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050046PR_NEWS_USPR_____CN63279) on October 05, 2026, and is solely responsible for the information contained therein.

  • Aroa Biosurgery reported results from a randomized trial of Symphony for diabetic foot ulcers, published in the International Wound Journal.
  • The study results have already been presented through publication, not flagged for a future conference release.
  • Patients receiving Symphony with standard care saw better healing outcomes than standard care alone, with more wounds closing fully.
  • Healing also occurred faster in the Symphony group, supporting a stronger clinical value proposition for reimbursement and adoption.
  • The trial enrolled 143 patients across 10 U.S. sites, targeting harder-to-treat ulcers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aroa Biosurgery Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050046PR_NEWS_USPR_____CN63279) on October 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Preview: PepsiCo earnings per share expected to be flat, investors focus on consumer spending

On October 7th, PepsiCo (PEP.O) shares fell by 1.4%, closing at $124.02. The company will release its quarterly earnings before market open on Thursday, and investors are closely watching for signs of pressure from tightening consumer budgets. According to data from the London Stock Exchange Group (LSEG), Wall Street expects the carbonated beverage and snack giant's Q3 revenue to grow approximately 4% year-on-year to $24.96 billions, with adjusted earnings per share (EPS) at $2.29, unchanged from a year ago. Last quarter, PEP's revenue exceeded expectations but the company warned that performance in North America would slow due to tighter consumer budgets. Facing cost pressures and the threat from GLP-1 weight-loss drugs, PepsiCo (PEP) has limited time left to meet the growth and margin targets set a year ago following activist investor Elliott Management’s $4 billions stake. So far this year, PEP share price has dropped about 14%, underperforming both the S&P 500 Soft Drink & Non-Alcoholic Beverage Index's 8% rise (.SPLRCBEVS) and the S&P 500 Consumer Staples Index's 6% gain (.SPLRCS). The stock is currently trading at a price-to-earnings ratio of 14, below its five-year average of 21. Among 25 analysts' recommendations: 7 rate it as “Strong Buy” or “Buy,” 17 rate it as “Hold,” and 1 rates it as “Sell.” The median target price is $152, down from $170 on July 7. (For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts, and provides them purely for readers’ convenience. Reuters assumes no liability for any damage or loss caused by the use of the automated translation function.)

路透社•2026/10/07 18:32

Tessera Defense and Homeland Security announces special shareholder meeting

Tessera Defense and Homeland Security will hold a special shareholder meeting in Netanya, Israel on Oct. 20, 2026. Votes will cover an amendment to the 2026 Equity Incentive Plan to increase shares available for equity awards. The proposal would support equity grants tied to CEO Michael Oster’s employment agreement, including stock options, RSUs, and fully vested shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tessera Defense and Homeland Security Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610071430PRIMZONEFULLFEED9841604) on October 07, 2026, and is solely responsible for the information contained therein.

Bitget•2026/10/07 18:30

Corteva Shares Rise After Upgrade From KeyBanc

02:22 PM EDT, 10/07/2026 (MT Newswires) -- Corteva (CTVA) shares were up 3.9% in afternoon trading on Wednesday after KeyBanc upgraded the company's stock to overweight from sector-weight. Trading volume exceeded 20.1 million shares against a daily average of roughly 10.4 million. Price: 14.45, Change: +0.54, Percent Change: +3.88

MT newswire•2026/10/07 18:22